CST BLOG

The official blog of Cell Signaling Technology, where we discuss what to expect from your time at the bench, share tips, tricks, and information.

An Open Letter Concerning Antibody Data Integrity

Read More →
All Posts

 

Recent media coverage describing the manipulation of validation data images used to promote commercial antibodies has brought critical issues of data integrity and reagent validation to the forefront.1,2 While scrutiny of product images and of the practices used to generate them is a vital component of improving research reproducibility, broad claims implying that inappropriate image manipulation is a universal practice among antibody suppliers misrepresent the market and add confusion rather than reducing it.

Significant differences exist in how suppliers operate, specifically regarding where the products they sell are actually developed, manufactured, and validated. The practice of sourcing, relabeling, and reselling antibodies is widespread across the industry. But it is by no means universal.3

How a supplier operates, and which operations and practices it prioritizes, can directly impact the integrity of its data. Unfortunately, some suppliers seem to prioritize having as broad an antibody catalog as possible, while minimizing the investment required to properly validate outsourced (or even in-house) antibodies. It is apparent that in the rush to expand catalogs, corners are being cut. This understandably erodes trust in suppliers that engage in data manipulation, but also casts a negative impression on the antibody market as a whole, with potentially serious implications for researchers who have published studies using these antibodies.

As scientists who perform research ourselves and collaborate with scientists around the world, we think all suppliers should be expected to provide:

  • Rigorous In-House Testing: When licensing hybridomas or sourcing an antibody from a third party, which could be another company, a contract lab, or an academic lab, suppliers should conduct their own in-house, application-specific testing using qualified materials to ensure performance.
  • Zero Data Reuse: Suppliers should not repost product data generated by third parties without disclosing the source. The images, graphs, and application data shown on product pages should reflect representative, real performance—not just cherry-picked results.
  • Appropriate image editing practices: While the judicious use of image editing tools to improve presentation clarity is valid, there must be no manipulation to hide poor results. Product images should be prepared WITHOUT image cloning, paintbrush operations, duplication or masking of bands, or any other selective image operations that change the meaning of the underlying data and misrepresent the performance of an antibody.

Data integrity is not just a commercial policy for us; it is a fundamental pledge.

Scientists should be able to trust the tools they use to advance discovery. When you view product data on our website, you can be assured that the information provided is honest, accurate, and reproducible in your own lab.

Science depends on trust, and we remain dedicated to earning yours every day.

 

Roberto Polakiewicz, PhD

Chief Scientific Officer, Cell Signaling Technology

 

References

  1. Garisto D. More than 18,000 questionable images found in antibody catalogues of 15 companies. Nature. Published online August 25, 2026. doi:10.1038/d41586-026-02635-w
  2. Richardson R, David S. Problematic images in vendor antibody verification data (version 260825). Zenodo. Published online August 25, 2026. doi:10.5281/zenodo.22090940
  3. The antibody supply chain: why we have 13,500 antibodies, not >100,000. Cell Signaling Technology Blog. Published September 2026. Accessed September 10, 2026. https://blog.cellsignal.com/antibody-supply-chain

26-bre-69300

26-HMC-18050

Roberto Polakiewicz, PhD
Roberto Polakiewicz, PhD
Roby drives research, product, and technology innovation, facilitating the creation of the most valuable CST products, technologies, and intellectual property. Roby has driven the creation and implementation of novel antibody technology platforms that have been critical to the company's success.

Recent Posts

Building Better Sandwich Immunoassays: A Toolbox for Biopharma Development Teams

Immunoassay development used to just mean getting a classic plate-based ELISA up and running. Today, that...

Inflammasome Therapeutics: How the Inflammasome Pathway is Being Targeted to Treat Chronic Diseases

Despite having essential roles in immune defense and tissue repair, inflammasomes contribute to the initi...
Emily Alonzo, PhD Oct 21, 2026

Huntington's Disease Biomarkers: Key Molecular Targets and Antibody Tools for HD Research

Proteins to Watch in Huntington's Disease Research When developing assays to study Huntington's disease (...
April Lowell, PhD Oct 16, 2026